Chugai Pharmaceutical Co., Ltd. – OTC:CHGCY
Chugai Pharmaceutical Co., Ltd. stock price today
$21.98
-0.51
-2.31%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Chugai Pharmaceutical Co., Ltd. stock price monthly change
+12.84%
month
Chugai Pharmaceutical Co., Ltd. stock price quarterly change
+12.84%
quarter
Chugai Pharmaceutical Co., Ltd. stock price yearly change
+19.05%
year
Chugai Pharmaceutical Co., Ltd. key metrics
Market Cap | 43.64B |
Enterprise value | 11.30T |
P/E | 16.46 |
EV/Sales | 10.41 |
EV/EBITDA | 23.13 |
Price/Sales | 10.77 |
Price/Book | 3.33 |
PEG ratio | -0.01 |
EPS | 198.37 |
Revenue | 1.03T |
EBITDA | 439.37B |
Income | 326.37B |
Revenue Q/Q | -24.11% |
Revenue Y/Y | -14.48% |
Profit margin | 32.74% |
Oper. margin | 44.34% |
Gross margin | 69.46% |
EBIT margin | 44.34% |
EBITDA margin | 42.41% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeChugai Pharmaceutical Co., Ltd. stock price history
Chugai Pharmaceutical Co., Ltd. stock forecast
Chugai Pharmaceutical Co., Ltd. financial statements
| Jun 2023 | 267.41B | 83.19B | 31.11% |
|---|---|---|---|
| Sep 2023 | 257.89B | 77.57B | 30.08% |
| Dec 2023 | 273.81B | 91.20B | 33.31% |
| Mar 2024 | 236.94B | 74.40B | 31.4% |
| 2025 | 1.12T | 179.33B | 15.88% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-10-24 | 0.17 | 0.15 |
|---|
0.62%
Yield TTM
| Payout ratio | 36.98% |
|---|
| 2019 | 2.04% |
|---|---|
| 2020 | 2.03% |
| 2021 | 3.19% |
| 2022 | 5.06% |
| 2023 | 3.03% |
| Jun 2023 | 1831590000000 | 318.26B | 17.38% |
|---|---|---|---|
| Sep 2023 | 1817649000000 | 282.65B | 15.55% |
| Dec 2023 | 1932547000000 | 306.96B | 15.88% |
| Mar 2024 | 1897764000000 | 255.71B | 13.47% |
| Jun 2023 | 126.67B | -9.55B | -2.36B |
|---|---|---|---|
| Sep 2023 | 31.29B | 1.99B | -67.38B |
| Dec 2023 | 124.56B | 5.20B | -2.21B |
| Mar 2024 | 101.77B | -33.10B | -66.87B |
Chugai Pharmaceutical Co., Ltd. alternative data
| Aug 2023 | 7,771 |
|---|---|
| Sep 2023 | 7,771 |
| Oct 2023 | 7,771 |
| Nov 2023 | 7,771 |
| Dec 2023 | 7,771 |
| Jan 2024 | 7,771 |
| Feb 2024 | 7,771 |
| Mar 2024 | 7,604 |
| Apr 2024 | 7,604 |
| May 2024 | 7,604 |
| Jun 2024 | 7,604 |
| Jul 2024 | 7,604 |
Chugai Pharmaceutical Co., Ltd. other data
Friday, 25 October 2024 | ||
| Chugai Pharmaceutical Co., Ltd. (CHGCF) Q3 2024 Earnings Call Transcript | seekingalpha.com | |
Saturday, 27 July 2024 | ||
| Chugai Pharmaceutical Co., Ltd. (CHGCF) Q2 2024 Earnings Call Transcript | seekingalpha.com | |
Monday, 18 March 2024 | ||
| Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | Zacks Investment Research | |
Wednesday, 6 March 2024 | ||
| Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's Why | Zacks Investment Research | |
Thursday, 12 October 2023 | ||
| Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Is a Great Choice for 'Trend' Investors, Here's Why | Zacks Investment Research | |
Thursday, 5 October 2023 | ||
| Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Upgraded to Buy: Here's What You Should Know | Zacks Investment Research | |
Friday, 21 April 2023 | ||
| 3 Stocks to Consider with Earnings Approaching | Zacks Investment Research |
-
What's the price of Chugai Pharmaceutical Co., Ltd. stock today?
One share of Chugai Pharmaceutical Co., Ltd. stock can currently be purchased for approximately $21.98.
-
When is Chugai Pharmaceutical Co., Ltd.'s next earnings date?
Unfortunately, Chugai Pharmaceutical Co., Ltd.'s (CHGCY) next earnings date is currently unknown.
-
Does Chugai Pharmaceutical Co., Ltd. pay dividends?
Yes, Chugai Pharmaceutical Co., Ltd. pays dividends and its trailing 12-month yield is 0.63% with 37% payout ratio. The last Chugai Pharmaceutical Co., Ltd. stock dividend of undefined was paid on 26 Sep 2025.
-
How much money does Chugai Pharmaceutical Co., Ltd. make?
Chugai Pharmaceutical Co., Ltd. has a market capitalization of 43.64B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 11.79% to 1.11T US dollars. Chugai Pharmaceutical Co., Ltd. earned 325.47B US dollars in net income (profit) last year or $0.15 on an earnings per share basis.
-
What is Chugai Pharmaceutical Co., Ltd.'s stock symbol?
Chugai Pharmaceutical Co., Ltd. is traded on the OTC under the ticker symbol "CHGCY".
-
What is Chugai Pharmaceutical Co., Ltd.'s primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—General industry.
-
How do i buy shares of Chugai Pharmaceutical Co., Ltd.?
Shares of Chugai Pharmaceutical Co., Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Chugai Pharmaceutical Co., Ltd. have?
As Jul 2024, Chugai Pharmaceutical Co., Ltd. employs 7,604 workers.
-
When Chugai Pharmaceutical Co., Ltd. went public?
Chugai Pharmaceutical Co., Ltd. is publicly traded company for more then 6 years since IPO on 21 Nov 2018.
-
What is Chugai Pharmaceutical Co., Ltd.'s official website?
The official website for Chugai Pharmaceutical Co., Ltd. is chugai-pharm.co.jp.
-
How can i contact Chugai Pharmaceutical Co., Ltd.?
Chugai Pharmaceutical Co., Ltd. can be reached via phone at +81 3 3281 6611.
Chugai Pharmaceutical Co., Ltd. company profile:
Chugai Pharmaceutical Co., Ltd.
chugai-pharm.co.jpExchange:
OTC
Full time employees:
7,664
Industry:
Drug Manufacturers—General
Sector:
Healthcare
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Nihonbashi Mitsui Tower
Tokyo, 103-8324
Tokyo, 103-8324
CIK: 0001453934
ISIN: US1712691039
CUSIP: 171269103
